Johnson & Johnson announces new data from Phase 3 ASTRO study of tremfya

Johnson & Johnson announced new data from the Phase 3 ASTRO study evaluating tremfya subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis. The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. FDA-approved intravenous induction regimen evaluated in this population, in the Phase 3 QUASAR study tremfya is the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen. These findings are among 24 abstracts highlighting the company’s research being presented at Digestive Disease Week 2025. Data at Week 24 show patients treated with tremfya 400 mg SC induction followed by SC maintenance dose regimens of either 100 mg every eight weeks or 200 mg every four weeks demonstrated statistically significant and clinically meaningful improvements across all clinical and endoscopic measures compared with patients receiving placebo. Furthermore, at Week 24, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, tremfya demonstrated statistically significant results across endpoints in both biologic and JAK inhibitor-naive and biologic and JAK inhibitor-refractory patients. Safety data from the ASTRO study were consistent with the well-established safety profile of tremfya.